Tradestie Institutional Equity Comparison Engine

CLRB vs BGMSP โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CLRB Overall Edge

CLRB Captures Institutional Edge (2โ€“1 Pillars ยท 6โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Cellectar Biosciences INC NEW (CLRB) driven by superior Growth & Margin, Momentum & Technical while BGMSP counters with relative strength in Options & Structure. Fundamentally, CLRB trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus BGMSP at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, CLRB sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against BGMSP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
CLRB N/M vs BGMSP N/M Fwd P/E
Growth & Margin Winner CLRB
Op Margin 0.0% vs N/A ยท YoY +0.0% vs N/A
Momentum & Technical Winner CLRB
1Y -63.8% vs -72.6% ยท 52W Pos 0% vs 0%
Options & Structure Winner BGMSP
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
CLRB NASDAQ
Cellectar Biosciences INC NEW
Pharmaceutical Preparations
$1.04
-8.77% 1D
Market Cap $11.6M
1M Return -8.77%
1Y Return -63.76%
Forward P/E N/M
Unified AI Score
39.4 / 100 SELL
Tech 25.0 Fund 49.0 Flow 44.0 Mom 64.0
BGMSP US Equity
BGMSP
Institutional Equity
$1.44
-39.75% 1D
Market Cap N/A
1M Return -60.98%
1Y Return -72.57%
Forward P/E N/M
Unified AI Score
42.7 / 100 HOLD
Tech 45.0 Fund 48.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CLRB -63.76% BGMSP -72.57% Spread: +84.13 pp (CLRB Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CLRB TTM Op. Margin: 0.0% BGMSP TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLRB vs BGMSP. Trailing 12-month operating profitability (CLRB 0.0% vs BGMSP N/A) and valuation multiples (CLRB N/M vs BGMSP N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CLRB (6) vs BGMSP (1)
Institutional Metric CLRB BGMSP Criterion Row Winner
Market Capitalization Scale $11.6M N/A Larger Scale CLRB
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% N/A Higher Growth CLRB
Operating Margin (TTM) Profitability 0.0% N/A Higher Margin CLRB
Net Profit Margin Profitability 0.0% N/A Higher Margin CLRB
Return on Equity (ROE) Capital Efficiency -162.6% N/A Higher ROE CLRB
52-Week Range Position Momentum 0% ($1โ€“$5) 0% ($1โ€“$14) Stronger Trend Tie
Beta / 30D Volatility Risk Regime 1.28ฮฒ ยท 81% Vol 0.59ฮฒ ยท 201% Vol Lower Realized Risk CLRB
Unified Institutional Score Composite Signal 39.4 / 100 (SELL) 42.7 / 100 (HOLD) Higher Composite BGMSP

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CLRB vs BGMSP Buy Guide
CLRB UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CLRB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BGMSP UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BGMSP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CLRB nor BGMSP registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.